Ethan Rowin to Treatment Outcome
This is a "connection" page, showing publications Ethan Rowin has written about Treatment Outcome.
Connection Strength
1.529
-
Fath AR, Aglan A, Maron MS, Phillips JS, Maron BJ, Rowin EJ. Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy. Int J Cardiol. 2025 May 01; 426:133082.
Score: 0.114
-
Massera D, Sherrid MV, Adlestein E, Bokhari N, Alvarez IC, Wu WY, Reuter MC, Maron MS, Maron BJ, Rowin EJ. Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5?Years. J Am Heart Assoc. 2025 Jan 21; 14(2):e037639.
Score: 0.113
-
Aglan A, Fath AR, Maron BJ, Maron MS, Prasad A, Almomani A, Hammadah M, Reynolds MR, Rowin EJ. Percutaneous left atrial appendage closure for stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation. Heart Rhythm. 2024 09; 21(9):1677-1683.
Score: 0.108
-
Rowin EJ, Link MS, Maron MS, Maron BJ. Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2023 11 28; 148(22):1797-1811.
Score: 0.105
-
Rowin EJ, Cooper C, Carrick RT, Tsoi M, Maron BJ, Maron MS. Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2022 09 15; 179:70-73.
Score: 0.095
-
Maron MS, Rosing DR, Braunwald E, Rastegar H, Koethe B, Roberts WC, Maron BJ, Rowin EJ. Sixty-Year Evolution of Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy with Insights From the Historic NIH Surgical Experience to Present. Am J Cardiol. 2022 06 01; 172:107-108.
Score: 0.093
-
Maron MS, Rastegar H, Dolan N, Carpino P, Koethe B, Maron BJ, Rowin EJ. Outcomes Over Follow-up =10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2022 01 15; 163:91-97.
Score: 0.091
-
Rowin EJ, Burrows A, Madias C, Estes NAM, Link MS, Maron MS, Maron BJ. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008123.
Score: 0.084
-
Kimmelstiel C, Rowin EJ. Fixed, high-volume alcohol dose for septal ablation: High risk with no benefit. Catheter Cardiovasc Interv. 2020 05 01; 95(6):1219-1220.
Score: 0.082
-
Rowin EJ, Kimmelstiel C. Combined alcohol septal ablation and transcatheter aortic valve replacement: Drunk and playing with fire. Catheter Cardiovasc Interv. 2020 03 01; 95(4):838-839.
Score: 0.081
-
Kimmelstiel C, Zisa DC, Kuttab JS, Wells S, Udelson JE, Wessler BS, Rastegar H, Kapur NK, Weintraub AR, Maron BJ, Maron MS, Rowin EJ. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. Circ Cardiovasc Interv. 2019 07; 12(7):e007673.
Score: 0.077
-
Rowin EJ, Maron BJ, Romashko M, Wang W, Rastegar H, Link MS, Maron MS. Impact of Effective Management Strategies on Patients With the Most Extreme Phenotypic Expression of Hypertrophic Cardiomyopathy. Am J Cardiol. 2019 07 01; 124(1):113-121.
Score: 0.076
-
Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, Maron MS. Hypertrophic Cardiomyopathy With Left?Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol. 2017 02 21; 69(7):761-773.
Score: 0.065
-
Narayanan CA, Bokhari N, Rowin EJ, Maron MS, Maron BJ, Link MS, Madias C. Maintenance of Subcutaneous Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy Patients With Iatrogenic Left Bundle-Branch Block After Septal Myectomy. J Am Heart Assoc. 2024 Apr 16; 13(8):e033728.
Score: 0.027
-
Faisaluddin M, Ahmed A, Patel H, Thakkar S, Patel B, Balasubramanian S, Feitell SC, Shekar P, Rowin E, Maron M, Ganatra S, Dani SS. Surgical Outcomes of Septal Myectomy With and Without Mitral Valve Surgeries in Hypertrophic Cardiomyopathy: a National Propensity-Matched Analysis (2005 to 2020). Am J Cardiol. 2023 10 15; 205:276-282.
Score: 0.026
-
Maron BJ, Dearani JA, Smedira NG, Schaff HV, Wang S, Rastegar H, Ralph-Edwards A, Ferrazzi P, Swistel D, Shemin RJ, Quintana E, Bannon PG, Shekar PS, Desai M, Roberts WC, Lever HM, Adler A, Rakowski H, Spirito P, Nishimura RA, Ommen SR, Sherrid MV, Rowin EJ, Maron MS. Ventricular Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy (Analysis Spanning 60 Years Of Practice): AJC Expert Panel. Am J Cardiol. 2022 10 01; 180:124-139.
Score: 0.024
-
Maron BJ, Rowin EJ, Ambe SP, Maron MS. Changing Demographics in Hypertrophic Cardiomyopathy and Implications for Management: Clinical Research. Am J Med. 2022 10; 135(10):1244-1246.
Score: 0.024
-
Cui H, Schaff HV, Wang S, Lahr BD, Rowin EJ, Rastegar H, Hu S, Eleid MF, Dearani JA, Kimmelstiel C, Maron BJ, Nishimura RA, Ommen SR, Maron MS. Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients?With Obstructive Hypertrophic?Cardiomyopathy. J Am Coll Cardiol. 2022 05 03; 79(17):1647-1655.
Score: 0.023
-
Butzner M, Sarocco P, Maron MS, Rowin E, Teng CC, Stanek E, Tan H, Robertson LA. Characteristics of Patients With Obstructive Hypertrophic Cardiomyopathy in Real-World Community-Based Cardiovascular Practices. Am J Cardiol. 2022 07 01; 174:120-125.
Score: 0.023
-
Maron MS, Rowin EJ, Maron BJ. Is surgical myectomy challenged by emergence of novel drug therapy with mavacamten? Asian Cardiovasc Thorac Ann. 2022 Jan; 30(1):11-18.
Score: 0.023
-
Boll G, Rowin EJ, Maron BJ, Wang W, Rastegar H, Maron MS. Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 01 01; 125(1):120-126.
Score: 0.020
-
Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, Koethe BC, Romashko M, Link MS, Maron BJ. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol. 2019 07 01; 4(7):644-657.
Score: 0.019
-
Miller CAS, Maron MS, Estes NAM, Price LL, Rowin EJ, Maron BJ, Link MS. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol. 2019 06 01; 123(11):1859-1862.
Score: 0.019
-
Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circ Arrhythm Electrophysiol. 2018 04; 11(4):e005820.
Score: 0.018
-
Solomon Z, Breton C, Rowin EJ, Maron BJ, Maron MS, Chen FY, Rastegar H. Surgical Approaches to Hypertrophic Obstructive Cardiomyopathy. Semin Thorac Cardiovasc Surg. 2018; 30(2):125-128.
Score: 0.018
-
Wells S, Rowin EJ, Boll G, Rastegar H, Wang W, Maron MS, Maron BJ. Clinical Profile of Nonresponders to Surgical Myectomy with Obstructive Hypertrophic Cardiomyopathy. Am J Med. 2018 06; 131(6):e235-e239.
Score: 0.017
-
Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR, Maron BJ, Maron MS, Maron BA. Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circ Heart Fail. 2017 Apr; 10(4):e003689.
Score: 0.016
-
Link MS, Bockstall K, Weinstock J, Alsheikh-Ali AA, Semsarian C, Estes NAM, Spirito P, Haas TS, Rowin EJ, Maron MS, Maron BJ. Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications. J Cardiovasc Electrophysiol. 2017 May; 28(5):531-537.
Score: 0.016
-
Wang W, Lian Z, Rowin EJ, Maron BJ, Maron MS, Link MS. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2017 Mar; 10(3).
Score: 0.016
-
Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience. J Am Heart Assoc. 2016 Feb 12; 5(2).
Score: 0.015